Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More
 

Investors

Attracting Support from Leading, Enthusiastic Investors

Our extensive expertise in exosome science, our best-in-class exosome technology platform and our multi-pronged strategy for building value have attracted support from prestigious investors. Our financial partners share our belief and enthusiasm in the tremendous potential of Exosome Diagnostics to transform the molecular diagnostics landscape, deliver on the promise of personalized precision medicine, and improve patients’ lives.

Multi-pronged strategy for building value - clinical diagnostics, research kits for lagoratory use, outcome-based research collaborations, pharma clinical trial and CDx partnerships.

Successful Series A and Series B Rounds

We have raised nearly $80 million in financings thus far from leading investors during our Series A and Series B rounds, including Forbion Capital Partners, NGN Capital, Arcus Ventures, Tiger Management, Blue Ridge Capital, QIAGEN, and CD Ventures.

Forbion Capital Partners

NGN Capital - New Global Network

Arcus Ventures

QIAGEN

To learn more, please contact ir@exosomedx.com.